Pallas Capital Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Pallas Capital Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$397K	Sell	6,941 -5,455	-44%	-$299K	0.01%	653
2026 Q1	$700K	Sell	12,396 -885	-7%	-$51.6K	0.03%	415
2025 Q4	$789K	Sell	13,281 -10,154	-43%	-$553K	0.03%	415
2025 Q3	$1.27M	Sell	23,435 -5,083	-18%	-$291K	0.05%	286
2025 Q2	$1.57M	Buy	28,518 +2,785	+11%	+$164K	0.06%	231
2025 Q1	$1.82M	Buy	25,733 +22,527	+703%	+$1.52M	0.08%	196
2024 Q4	$211K	Sell	3,206 -3,938	-55%	-$264K	0.01%	545
2024 Q3	$503K	Buy	+7,144	New	+$597K	0.02%	356

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Pallas Capital Advisors's BMRN Position: Q2 2026 in Review

Pallas Capital Advisors reduced its BioMarin Pharmaceuticals (BMRN) stake by 44% in Q2 2026, selling an estimated $299K and leaving 6,941 shares worth $397K. The position accounts for 0.01% of the portfolio, ranked #653.

Pallas Capital Advisors first reported a position in BMRN in Q3 2024 and has held it in 8 quarters since. The position peaked at $1.82M in Q1 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Pallas Capital Advisors held 6,941 shares of BioMarin Pharmaceuticals worth $397K as of Q2 2026.
Pallas Capital Advisors sold 5,455 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $299K.
BioMarin Pharmaceuticals made up 0.01% of Pallas Capital Advisors's portfolio in Q2 2026, its #653 holding.
Pallas Capital Advisors first reported a position in BioMarin Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
Pallas Capital Advisors's BioMarin Pharmaceuticals position peaked at $1.82M in Q1 2025.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Pallas Capital Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.